{"id":"NCT01967784","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan","officialTitle":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-04","completion":"2014-07","firstPosted":"2013-10-23","resultsPosted":"2016-01-20","lastUpdate":"2016-01-20"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Influenza Vaccine (split virion, inactivated)","otherNames":[]}],"arms":[{"label":"Study Group","type":"EXPERIMENTAL"}],"summary":"The aim of the study is to describe the immunogenicity and safety of the new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season in the Northern Hemisphere (NH) in subjects aged 9 to 17 years in Taiwan\n\nPrimary Objective:\n\n* To describe the immunogenicity of the QIV (split-virion, inactivated) NH seasonal formulation\n\nSecondary Objective:\n\n* To describe the safety of the QIV (split-virion, inactivated) NH seasonal formulation","primaryOutcome":{"measure":"Geometric Mean Titers of Influenza Antibodies Before and Following Vaccination With a Quadrivalent Influenza Vaccine","timeFrame":"Day 0 (pre-vaccination) and Day 21 post-vaccination","effectByArm":[{"arm":"Quadrivalent Influenza Vaccine","deltaMin":257,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":2,"countries":["Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Injection site Pain","Myalgia","Malaise","Nasopharyngitis","Headache"]}}